¿Section 1:¿HEPATITIS: ADVANCES IN CLINICAL EVALUATION 1. Noninvasive assessment of liver disease severity: image-related2. Noninvasive assessments of liver disease severity based on biomarkers3. Conventional liver imaging in hepatitis4. Nutrition in liver disease
Section II: VIRAL HEPATITIS 5. Antivirals against hepatitis viruses: basic mechanisms6. Hepatitis A and hepatitis E7. Hepatitis B: epidemiology, natural history, and diagnosis8. Hepatitis B: treatment9. Hepatitis C: epidemiology, natural history, and diagnosis10. Hepatitis C: treatment11. Hepatitis D
Section III: HEPATITIS: METABOLIC, ALCOHOL, AND DRUG INDUCED12. Metabolic-associated fatty liver disease: epidemiology, natural history and diagnosis, current paradigm and definitions for MAFLD13. Metabolic-associated fatty liver disease: pharmacological management14. Non-pharmacological treatment approach in patients with metabolic dysfunctionassociated liver disease15. Alcoholic hepatitis16. Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method17. Introduction to drug-induced liver injury
Section IV: HEPATITIS: CHOLESTATIC, GENETIC, AND AUTOIMMUNE CAUSES18. Current paradigm and treatment options for autoimmune hepatitis19. Hereditary hemochromatosis20. Wilson disease21. Alpha-1 antitrypsin deficiency
Section V: HEPATITIS: INFECTIONS AND SYSTEMIC CAUSES22. Hepatitis: infections and systemic causes23. HIV: hepatic manifestations of HIV and antiretroviral therapy24. Systemic non-infectious hepatitis25. Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection
Section VI: CHILDHOOD AND PREGNANCY26. Hepatitis during childhood27. Hepatitis during pregnancy
